Lantheus Holdings announced the sale of its CDMO business and Springfield, New Jersey facility to PharmaLogic, while securing a long-term supply agreement for lutetium Lu 177 dotatate production.
On November 8, 2026 Lantheus agreed to sell its CDMO business and Springfield, New Jersey facility to PharmaLogic, while PharmaLogic's Agilera unit will manufacture lutetium Lu 177 dotatate under a long-term supply agreement. A definitive divestiture is a material structural change, but the 8-K discloses no purchase price or financial terms, so the net effect on valuation cannot be judged. The supply agreement secures manufacturing for a key product, which supports the strategic rationale.
Lantheus Holdings, Inc. entered into a definitive agreement on November 8, 2026, to divest its contract development and manufacturing organization (CDMO) business and its Springfield, New Jersey facility to PharmaLogic. As part of the transaction, the companies established a long-term supply agreement where PharmaLogic’s Agilera unit will manufacture lutetium Lu 177 dotatate for Lantheus.
That on November 8, 2026 it signed a definitive agreement to sell its CDMO business and its Springfield, New Jersey manufacturing facility to PharmaLogic, and that PharmaLogic's Agilera unit will manufacture lutetium Lu 177 dotatate for Lantheus under a long-term supply agreement.
The filing does not disclose any purchase price or financial terms for the sale.